[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100339378":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":7,"centralContacts":17,"locations":7,"responsibleParty":27,"collaborators":7,"id":29,"slug":30,"hasResults":31,"nctId":32,"briefTitle":33,"officialTitle":34,"acronym":35,"eligibilityCriteria":36,"healthyVolunteers":31,"sex":37,"minAge":38,"maxAge":7,"enrollmentInfo":39,"targetDuration":7,"studyType":42,"phases":7,"briefSummary":43,"conditions":44,"keywords":50,"overallStatus":55,"whyStopped":7,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":7},{"fullName":5,"class":6},"Central Hospital, Nancy, France","OTHER",null,[9],{"type":10,"name":11,"description":12,"armGroupLabels":7,"otherNames":13},"PROCEDURE","Transurethral Resection of Prostate","Transurethral resection of the prostate is a urological operation used to treat benign prostatic hyperplasia (BPH). It is performed by visualising the prostate through the urethra and removing tissue by electrocautery or sharp dissection with a resectoscope. This is considered the most effective treatment for BPH. This procedure is done with spinal or general anaesthetic. A triple lumen catheter is inserted through the urethra to irrigate and drain the bladder after the surgical procedure is complete. Outcome is considered excellent for 80-90% of BPH patients.",[14,15,16],"TURP","TURPs","TUPR",[18,23],{"name":19,"role":20,"phone":21,"phoneExt":7,"email":22},"Nicolas Berte, Dr","CONTACT","00333673004195","n.berte@chru-nancy.fr",{"name":24,"role":20,"phone":25,"phoneExt":7,"email":26},"Jean-Louis Lemelle, PHD","0033383154729","jl.lemelle@chru-nancy.fr",{"type":28,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100339378","urothelium-tissue-engineering-using-biopsies-from-transurethral-resection-of-prostate-100339378",false,"NCT03698721","Urothelium Tissue Engineering Using Biopsies From Transurethral Resection of Prostate","Urothelium Tissue Engineering Using Bladder Mucosa From Transurethral Resection of Prostate","IMOPU","Inclusion Criteria:\n\n* Patient needing a Transurethral Resection of Prostate (TURP)\n* Weight of prostate (evaluated by ultrasonography)greater than or equal to 30 grams\n* Affiliation to a social security system\n* Patient over the age of majority\n* Patient receiving complete information on research organization without opposition to the use of biological specimen\n\nExclusion Criteria:\n\n* Patient for whom no TURP is realized during endoscopic procedure\n* Patient for whom no resection is realized on the bladder neck\n* Patient with prostate weight estimated under 30 grams\n* Patient who opposed to the realization of the study","MALE","18 Years",{"count":40,"type":41},365,"ESTIMATED","OBSERVATIONAL","Different clinical conditions can require urinary bladder augmentation or replacement. Tissue engineered bladder has been clinically evaluated but is not recommended due to diverse side effects. Thus, there is a real interest for the development of regenerative approach with innovative scaffolds and cell transplantation.\n\nThe investigators propose the use of urothelial cells obtained by Trans-Urethral Resection of Prostate or bladder (TURP) to obtain a tissue engineered urothelium in association with different scaffolds.",[45,46,47,48,49],"Spina Bifida","Urothelial Neoplasm","Bladder, Neurogenic","Bladder Exstrophy","Hypospadias",[51,52,53,54],"Tissue engineering","Collagen scaffold","Alginate scaffold","Urothelial cells","NOT_YET_RECRUITING","2018-10-04",{"date":58,"type":59},"2018-10-09","ACTUAL",{"date":61,"type":41},"2018-10",{"date":63,"type":41},"2026-10",{"name":5,"class":6}]